细胞和基因治疗市场按治疗类型、给药方式、治疗领域、应用和最终用户划分－2025-2032年全球预测

预计到 2032 年，细胞和基因治疗市场将成长至 713.8 亿美元，复合年增长率为 19.95%。

关键市场统计数据
基准年 2024	166.5亿美元
预计年份：2025年	194.7亿美元
预测年份 2032	713.8亿美元
复合年增长率 (%)	19.95%

本文提供了一个简洁的策略框架，阐述了科学进步、製造过程的复杂性以及政策动态如何重塑细胞和基因治疗生态系统。

细胞和基因治疗生态系统正处于曲折点，科学突破与营运和商业上的复杂性交汇融合。载体工程、精准基因编辑和过继细胞技术的进步已将过去的理论介入措施转化为临床现实。同时，相关人员努力应对生产瓶颈、专业的低温运输物流以及不断变化的监管要求，这需要产业界、学术界和服务供应商之间协调一致的应对措施。

本执行摘要摘要了这些转变对必须平衡创新与规模的领导者的策略意义。它综合分析了新兴技术发展轨迹、供应链脆弱性、支付者和医疗系统动态，以及影响跨境活动的政策环境。其目的是为决策者提供清晰的叙述和实用的视角，以评估近期营运重点和中期策略选择。透过将技术进步与商业性和监管现实联繫起来，它重点介绍了可能带来差异化价值的投资和伙伴关係。

本摘要着重于可操作的见解，而不是抽象的趋势，使您能够将您的研发蓝图、製造投资和市场加速策略与当前情况中最关键的成功因素保持一致。

科技、管理、监管和商业性力量如何融合，为细胞和基因治疗相关人员创造新的策略要务？

细胞和基因治疗领域正经历多维度的变革，这些变革相互交织，重新定义了竞争优势。技术进步提高了治疗的特异性和持久性，而基因编辑平台和载体设计的创新则减少了脱靶效应，并拓宽了治疗范围。同时，生产製造也从客製化、小批量生产转向更标准化、模组化的方法，优先考虑稳健性、可重复性和成本控制。这种营运模式的演变，使得新一代的受託製造和平台提供者能够提供可扩展的解决方案。

法律规范正在不断调整以适应快速发展的科学，日益重视真实世界证据、适应性试验设计和生命週期监测模型。支付方的参与也在日趋成熟，基于结果的合约和分期付款结构正逐渐成为连结高昂前期成本和长期临床价值的有效机制。地缘政治和贸易动态促使申办方重新评估其供应链策略，对区域製造和供应商多元化的兴趣日益浓厚。因此，伙伴关係和网路编配正成为关键的策略槓桿。能够在分散式价值链中整合发现、开发和交付环节，同时保持对核心智慧财产权控制的公司，将更有可能获得竞争优势。

综上所述，这些变化将有利于那些能够将卓越的科学技术与严谨的管理、敏锐的监管意识和商业性创造力相结合的组织，从而将治疗方法从有前景的科学转化为永续的患者可及性。

评估近期关税政策变化对先进治疗药物供应链、本地化生产和风险管理策略的多方面影响

美国2025年关税政策的改变将为细胞和基因治疗产业带来新的挑战。试剂、特殊原料和某些生技药品成分的关税可能会迫使采购团队重新评估供应商关係和库存策略。对于依赖少数关键供应商的公司而言，关税将奖励它们寻找合格的替代供应商或将部分供应链本地化，以降低成本波动和海关延误带来的影响。

除了直接成本影响外，关税政策还会影响与生产地点相关的资本配置决策。企业越来越倾向于权衡建设区域生产能力和维持集中式生产设施（以便获得规模经济效益）之间的利弊。关税可能会使国内或近岸生产更具经济吸引力，从而加速区域化进程，但也可能扰乱供应链，并增加对冗余检验流程的需求。物流也同样受到影响。清关时间和额外的单据要求可能会对温度敏感产品的低温运输完整性造成压力，促使企业加大对紧急运输方案和运输途中品质监控的投资。

从策略角度来看，关税环境可能会促使企业深化与上游工程供应商的合作，推行结合合约保护和双重采购的综合筹资策略，并加强情境规划以模拟政策变化。对于监管机构和行业协会而言，这意味着需要加强对话力度，以确保贸易措施不会因造成过重的行政负担而无意中阻碍患者获得治疗或促进创新。总之，关税不仅影响细胞和基因治疗计画的成本结构，也影响其全球製造和风险管理架构。

主导细分市场的综合分析揭示了治疗方式、给药途径、治疗适应症、最终用途和最终用户画像如何影响商业性和营运选择。

深入的细分能清楚展现临床前景与实际营运的交会点，帮助领导者精准地分配资源。细胞疗法分为干细胞疗法和T细胞疗法；干细胞疗法可细分为造血干细胞疗法和间质干细胞疗法；T细胞疗法分为CAR-T细胞疗法和T细胞受体疗法；基因疗法则分为体外基因疗法和体内基因疗法，二者各自独特的载体、递送方式和安全性特征都会影响研发进度以及与监管机构的沟通。

给药途径细分突显了临床实施和病患管理的差异，肌肉注射和静脉注射需要不同的给药训练、输注能力和监测。治疗领域细分揭示了疾病生物学如何决定治疗方法的选择和销售管道。心血管应用着重于心臟衰竭郁血性和缺血性心臟疾病；代谢性疾病研究着重于糖尿病和肥胖症；神经病学计画着重于阿兹海默症、亨廷顿舞蹈症、多发性硬化症、帕金森氏症和脊髓损伤等疾病；肿瘤学研究着重于骨髓恶性肿瘤、淋巴瘤和固态肿瘤。基于应用的细分将临床应用与研发活动区分开来，前者进一步分为疾病预防和疾病治疗，反映了监管终点和支付方期望的差异。最后，最终用户细分认识到学术和研究机构与医院和诊所之间不同的采购和采用动态，这些机构又进一步细分为推动研究者主导的研究和转化流程的私人实验室和大学。

了解这些重迭的细分市场，可以将技术能力与每个细分市场相关的特定监管、临床和支付方路径结合，从而更有针对性地进行临床试验设计、生产布局规划和商业化策略。

区域策略动态和基础设施的考量将决定临床开发、生产能力和市场推广倡议的选址。

区域动态对细胞和基因治疗领域的研发策略、监管环境和供应链设计有着深远的影响。在美洲，创新丛集汇聚了临床专业知识、先进的製造能力和创业投资资金生态系统，以支援快速转化应用，但相关人员必须应对复杂的支付方格局和各州政策的差异。该地区的法规环境高度重视严谨的临床证据，并辅以早期准入途径以促进有条件核准。在营运方面，毗邻主要学术中心有利于建立伙伴关係关係，从而加速早期临床试验。

欧洲、中东和非洲地区（EMEA）的监管模式和报销体係错综复杂。欧洲部分地区提供协作评估框架和卫生技术评估途径，以奖励长期价值，而其他地区则要求大量的本地证据收集工作。随着产能投资和专业服务供应商的涌现，该地区的製造业格局正在不断发展，但企业在该地区开展业务时必须协调不同的跨境监管环境和多样化的医疗保健资金筹措机制。在基础设施仍然欠发达的地区，能力建设措施和官民合作关係对于扩大医疗服务覆盖至关重要。

亚太地区拥有快速成熟的临床试验能力，并制定了雄心勃勃的国家策略，试图成为生物技术製造和商业化中心。该地区各国政府都在投资生物技术基础设施、放宽先进疗法的管制，并进行人才培养计画。虽然申办方能够接触到庞大的患者群体并降低研发成本，但他们也必须应对监管预期、区域生产要求和市场准入标准方面的差异。

针对这些区域差异制定策略至关重要，以便使试验设计、生产安排和商业性准入计划与当地监管现实和支付方期望保持一致。

企业策略如何透过聚焦整合、平台专业化和服务卓越来重塑细胞和基因治疗价值链的竞争格局？

在先进疗法领域，各公司层面的策略正围绕着一系列核心能力趋于一致，这些核心能力将决定哪些公司能够胜出，哪些公司将落败。领先企业正投资于垂直整合的能力，涵盖药物发现、载体和细胞工程、製程开发以及商业化规模生产，同时保持灵活的伙伴关係，以实现产能的快速扩张。其他企业则专注于平台技术，例如模组化生产系统、高效价载体生产或封闭式细胞处理系统，并透过授权或合约服务的方式运作这些技术，从而实现规模化和可重复性带来的价值。

服务供应商和契约製造製造商正发挥日益重要的策略作用，他们提供端到端的解决方案，加快申办方启动临床试验的速度并降低技术风险。在品质系统、法规遵循和供应编配方面表现卓越的公司，透过确保生产效率和最大限度地减少产品交付延迟，确保与申办方建立长期合作关係。同时，研发方正透过临床项目设计、基于生物标誌物的患者筛选以及与支付方的沟通策略来脱颖而出，将临床获益转化为可信的卫生经济学论证。

投资者和公司发展活动主要集中在解决行业最紧迫的瓶颈问题：可扩展的载体生产、自动化细胞处理、可靠的滴度和可比性分析、数位化批次记录系统等。对于这类公司而言，成功与否取决于能否证明其生产过程可重复、临床结果可靠，以及商业化计划能够考虑到报销的复杂性和国际市场准入壁垒。

领导者可采取切实可行的策略重点，以增强供应链韧性、扩大生产规模、协调监管策略并加快支付方采纳。

产业领导者应优先采取一系列切实可行的措施，将卓越的科学研究成果转化为持续的商业性成功。首先，加强供应商伙伴关係并对关键投入品进行双重采购，可以降低地缘政治和关税波动带来的风险，同时确保临床供应的连续性。此外，投资模组化生产能力和自动化技术可以降低批次差异，提高单位成本，从而为内部生产和契约製造伙伴关係创造更多选择。同时，制定清晰的监管沟通计划，纳入真实世界证据策略和核准后数据收集，可以加快与支付方的对话，并支持基于结果的合约模式。

在营运层面，各组织应加快品质系统和批次分析的数位化，以实现更具预测性的生产控制和更快的监管申报。研发、生产和商业团队之间的跨职能协作至关重要。将临床里程碑与生产准备和市场准入要求相衔接的一体化计划管治，能够减少后期开发阶段的延误。与医疗服务提供者合作设计可行的给药途径，可确保患者获得治疗并简化应用流程，尤其对于需要专业输液中心的复杂细胞疗法更是如此。

最后，基于情境的策略规划，透过模拟关税、监管变化和产能限制等因素的影响，可以帮助领导团队确定投资和伙伴关係选择的优先顺序。透过结合供应链韧性、生产扩充性、监管前瞻性和以支付方为中心的证据生成，行业领导者可以降低其发展路径的风险，并建立永续的患者获取途径。

采用严谨的混合方法研究途径，结合主要相关人员访谈、监管和专利分析以及流程图检验，以验证营运和策略洞察。

本分析整合了多方面的证据，建构了一个稳健且可重复的细胞和基因治疗领域当前动态图景。主要研究包括对相关人员进行结构化访谈，这些利害关係人包括研发机构、临床开发团队、生产和供应链负责人、监管事务专业人员以及支付方。次要研究则利用同行评审文献、已发布的监管指南、临床试验註册资讯、公司披露资讯、专利申请以及物流和低温运输研究，检验了营运和科学趋势。

分析技术包括：绘製製造工作流程图以识别通用瓶颈；进行比较监管分析以揭示不同司法管辖区的差异；以及对专家访谈进行定性编码以突出反復出现的战略主题。情境分析用于评估关税变化和供应链中断对营运的影响。必要时，透过与相关领域专家最后覆核检验研究结果，以减少偏差并确保技术准确性。限制包括：该行业的技术创新速度较快，这可能导致能力和法规的快速变化；以及独特的製造流程差异，这限制了所有研发公司之间的直接可比较性。

儘管存在这些局限性，调查方法强调三角测量和同行检验，以产生可用于策略决策、投资评估和营运规划的可操作见解。

将科学进步与商业性准备及途径有效整合，进而实现患者持续用药及业务永续性。

细胞和基因治疗领域正进入一个新阶段，策略执行而非单纯的科学新颖性将决定哪些治疗方法可以取得持续的临床和商业性成功。儘管科学进步不断拓展可治疗疾病的范围并提高干预的精准度，但通往患者的道路仍需关註生产规模化、供应链稳健性、监管合规以及支付方证据的获取。那些积极建立稳健的供应商网络、采用模组化生产和数位化品质体系，并以可信的真实世界证据与支付方沟通的领导者，将更有能力将临床成功转化为广泛的患者可及性。

全球策略必须灵活，并根据各地区情况进行调整，因为区域监管方式、关税趋势和商业模式相互影响。将平台投资与明智的伙伴关係关係结合，并运用情境规划应对地缘政治和政策变化的组织可以降低执行风险。尤其重要的是，在整个组织内整合科学、营运和商业性计划可以加速从示范到部署的过渡，确保治疗方法惠及有需要的患者，同时维持永续的经营模式。

综上所述，这些优先事项为在竞争激烈且快速变化的环境中将创新转化为实际影响提供了切实可行的蓝图。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 利用通用捐赠者平台扩大针对固体癌的同种异体CAR-T细胞疗法的规模
• 将基于 CRISPR 的基因编辑技术应用于罕见遗传疾病的体内治疗，以提高安全性和疗效。
• 采用自动化封闭式系统製造，以降低成本并扩大个人化细胞疗法的生产规模。
• 开发新一代AAV载体平台，以增强基因治疗中的组织特异性并降低免疫抗原性
• 实施分散式照护现场生产模式，用于自体细胞疗法的现场生产
• 能够克服免疫抑制性肿瘤微环境的多特异性CAR T细胞构建体的出现
• 生技公司与CDMO建立策略伙伴关係关係，加速细胞疗法的临床开发与商业化
• 监管协调工作旨在简化全球核准途径，加快患者获得基因疗法的速度。
• 应用人工智慧数位双胞胎对细胞治疗生产流程进行分析和优化
• 对供应链创新（包括冷冻保存和低温运输物流）的投资，确保了细胞产品在全球的可行性。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按治疗类型分類的细胞和基因治疗市场

• 细胞疗法
  • 干细胞疗法
    • 造血干细胞疗法
    • 间质干细胞疗法
  • T细胞疗法
    • CAR-T细胞疗法
    • 基于T细胞受体（TCR）
• 基因治疗
  • 体外基因治疗
  • 体内基因治疗

9. 按给药方式分類的细胞和基因治疗市场

• 肌肉内注射
• 静脉

第十章 按治疗领域分類的细胞和基因治疗市场

• 心血管系统
  • 郁血性心臟衰竭
  • 缺血性心臟疾病
• 代谢紊乱
  • 糖尿病
  • 肥胖
• 神经系统疾病
  • 阿兹海默症
  • 亨丁顿舞蹈症
  • 多发性硬化症
  • 帕金森氏症
  • 脊髓损伤
• 肿瘤学
  • 骨髓恶性肿瘤
  • 淋巴瘤
  • 固态肿瘤
• 眼科

第十一章 按应用分類的细胞和基因治疗市场

• 临床应用
  • 疾病预防
  • 疾病治疗
• 研究与开发

第十二章 依最终用户分類的细胞和基因治疗市场

• 学术和研究机构
  • 私人研究机构
  • 大学
• 医院和诊所

第十三章 细胞与基因治疗市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 细胞与基因治疗市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国细胞与基因治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • AGC Inc.
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc
  • Astellas Pharma Inc.
  • Becton, Dickinson and Company
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cellectis SA
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Mustang Bio, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • REGENXBIO Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Shoreline Biosciences
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated

The Cell & Gene Therapy Market is projected to grow by USD 71.38 billion at a CAGR of 19.95% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 16.65 billion
Estimated Year [2025]	USD 19.47 billion
Forecast Year [2032]	USD 71.38 billion
CAGR (%)	19.95%

A concise strategic framing of how scientific advances, manufacturing complexity, and policy dynamics are reshaping the cell and gene therapy ecosystem

The cell and gene therapy ecosystem stands at an inflection point where scientific breakthroughs are converging with operational and commercial complexity. Advances in vector engineering, gene editing precision, and adoptive cell technologies have moved previously theoretical interventions into clinical reality. At the same time, stakeholders are grappling with manufacturing bottlenecks, specialized cold-chain logistics, and evolving regulatory expectations that require coordinated responses across industry, academia, and service providers.

This executive summary distills the strategic implications of these shifts for leaders who must balance innovation with scale. It synthesizes emerging technology trajectories, supply chain vulnerabilities, payer and health system dynamics, and the policy environment shaping cross-border activity. The intent is to equip decision-makers with a clear narrative and practical lenses to evaluate near-term operational priorities and medium-term strategic options. By linking technical advances to commercial and regulatory realities, the analysis clarifies where investments and partnerships are most likely to deliver differentiated value.

Throughout this summary, emphasis is placed on executable insights rather than abstract trends, enabling teams to align R&D roadmaps, manufacturing investments, and go-to-market strategies with the most consequential drivers of success in the current landscape.

How converging technological, operational, regulatory, and commercial forces are creating new strategic imperatives for cell and gene therapy stakeholders

The landscape for cell and gene therapies is transforming along multiple, interlocking dimensions that together redefine competitive advantage. Technological advances are improving specificity and durability of treatments, with innovations in gene-editing platforms and vector design reducing off-target effects and broadening therapeutic applicability. Concurrently, manufacturing is transitioning from bespoke, small-batch processes to more standardized modular approaches that prioritize robustness, reproducibility, and cost control. This operational evolution is enabling a new class of contract manufacturing organizations and platform providers to offer scalable solutions.

Regulatory frameworks are adapting to accommodate rapid scientific progress, increasingly emphasizing real-world evidence, adaptive trial designs, and lifecycle oversight models. Payer engagement is also maturing, with outcome-based contracting and installment payment structures emerging as viable mechanisms to bridge high upfront costs and long-term clinical value. Geopolitical and trade dynamics are prompting sponsors to reassess supply chain strategies, driving interest in regional manufacturing and supplier diversification. As a result, partnerships and network orchestration are becoming central strategic levers: companies that can integrate discovery, development, and delivery across a distributed value chain while retaining control of core intellectual property will gain advantage.

Taken together, these shifts favor organizations that can couple scientific excellence with operational discipline, regulatory acuity, and commercial creativity, enabling therapies to move from promising science to sustainable patient access.

Assessing the multifaceted effects of recent tariff policy changes on supply chains, manufacturing localization, and risk management strategies in advanced therapies

The implementation of tariff changes in the United States in 2025 introduces a new layer of complexity for the cell and gene therapy sector, particularly because the industry relies on globally sourced inputs and cross-border manufacturing chains. Tariffs on reagents, specialized raw materials, and certain biologics components can drive procurement teams to re-evaluate supplier relationships and inventory strategies. For organizations dependent on a narrow set of critical suppliers, tariffs increase the incentive to qualify alternate suppliers or to localize portions of the supply chain to mitigate cost volatility and customs-related delays.

Beyond direct cost impacts, tariff policy influences capital allocation decisions related to manufacturing geography. Firms are increasingly weighing the trade-offs between building regional production capacity and maintaining centralized facilities that benefit from scale. Tariffs can accelerate regionalization by making domestic or nearshore production economically more attractive, but they can also fragment supply networks and amplify the need for redundant validation streams. Logistics flows are likewise affected: customs processing times and additional documentation requirements can stress cold-chain integrity for temperature-sensitive products, prompting greater investment in contingency transport options and quality monitoring across transit.

Strategically, the tariff environment will push companies to deepen upstream engagement with suppliers, to pursue integrated sourcing strategies that combine contractual protections with dual sourcing, and to enhance scenario planning that models policy shifts. For regulators and industry associations, the implications include a greater call for dialogue to ensure that trade measures do not inadvertently impede patient access or innovation by introducing excessive administrative burden. In sum, tariffs shape not only cost structures but also the architecture of global manufacturing and risk management for cell and gene therapy programs.

A segmentation-driven synthesis revealing how therapy modality, delivery route, therapeutic indication, application use case, and end-user profile shape commercial and operational choices

Insightful segmentation clarifies where clinical promise intersects with operational realities and allows leaders to prioritize resources with precision. When the market is parsed by therapy modality, distinct development and manufacturing pathways emerge: cell therapies divide into stem cell approaches and T cell-based approaches, with stem cell therapies further delineated into hematopoietic stem cell therapies and mesenchymal stem cell therapies, while T cell strategies separate into CAR T cell therapy and T cell receptor-based approaches. Gene therapies introduce another axis of differentiation, distinguishing ex vivo gene therapy from in vivo gene therapy, each carrying unique vector, delivery, and safety profiles that influence development timelines and regulatory interactions.

Delivery method segmentation underscores differences in clinical implementation and patient management, with intramuscular and intravenous approaches presenting divergent requirements for administration training, infusion capacity, and monitoring. Therapeutic area segmentation highlights how disease biology drives modality choice and commercial pathways: cardiovascular applications focus on congestive heart failure and ischemic heart disease, metabolic disorder efforts emphasize diabetes and obesity, neurological programs concentrate on conditions such as Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, and spinal cord injuries, and oncology initiatives pivot across hematological malignancies, lymphomas, and solid tumors. Application-based segmentation separates clinical applications from research and development activities, with the former further parsed into disease prevention and disease treatment, reflecting differing regulatory endpoints and payer expectations. Finally, end-user segmentation recognizes divergent purchasing and adoption dynamics between academic and research institutes and hospitals and clinics, with academic and research institutes further distinguished into private research labs and universities that shape investigator-initiated studies and translational pipelines.

Understanding these overlapping segments enables more targeted clinical trial design, manufacturing footprint planning, and commercialization strategies by aligning technical capabilities with the specific regulatory, clinical, and payer pathways associated with each segment.

Regional strategic dynamics and infrastructure considerations that determine where to locate clinical development, manufacturing capacity, and market access initiatives

Regional dynamics exert a powerful influence on development strategies, regulatory approaches, and supply chain design across the cell and gene therapy landscape. In the Americas, innovation clusters concentrate clinical expertise, advanced manufacturing capabilities, and venture funding ecosystems that support rapid translational activity, but stakeholders must manage complex payer landscapes and heterogeneous state-level policies. The regulatory environment in the region reflects an emphasis on rigorous clinical evidence combined with early access pathways that can facilitate conditional approvals; operationally, proximity to major academic centers supports partnerships that accelerate early-phase trials.

The Europe, Middle East & Africa region presents a mosaic of regulatory models and reimbursement systems. While some European jurisdictions offer collaborative assessment frameworks and health technology assessment pathways that reward long-term value, others require extensive local evidence generation. The region's manufacturing landscape is evolving with investments in capacity and specialized service providers, yet companies navigating this geography must reconcile cross-border regulatory variances and diverse healthcare funding mechanisms. Capacity-building initiatives and public-private partnerships are increasingly important levers to expand access in parts of the region where infrastructure remains nascent.

Asia-Pacific combines rapidly maturing clinical trial capabilities with ambitious national strategies to become hubs for biotechnology manufacturing and commercialization. Governments across the region are investing in biotechnology infrastructure, streamlined regulatory pathways for advanced therapies, and talent development programs. This creates both opportunity and complexity: sponsors can access large patient populations and lower development costs, but must also adapt to different regulatory expectations, local manufacturing requirements, and market access criteria.

Attuning strategy to these regional differences is essential for aligning trial design, manufacturing placement, and commercial access plans with local regulatory realities and payer expectations.

How company strategies focused on integration, platform specialization, and service excellence are reshaping competitive positioning across the cell and gene therapy value chain

Company-level strategies are converging around a set of core capabilities that differentiate winners from also-rans in the advanced therapy arena. Leading organizations are investing in vertically integrated capabilities that span discovery, vector and cell engineering, process development, and commercial-scale manufacturing, while also maintaining flexible partnerships that allow rapid capacity expansion. Others are specializing in platform technologies-such as modular manufacturing systems, high-titer vector production, or closed-system cell processing-that they can license or operate as contract services, thereby capturing value through scale and reproducibility.

Service providers and contract manufacturers are playing an increasingly strategic role by offering end-to-end solutions that reduce time-to-clinic for sponsors and lower technical risk. Companies that excel in quality systems, regulatory compliance, and supply chain orchestration are securing long-term relationships with sponsors by guaranteeing throughput and minimizing release delays. Meanwhile, developers are differentiating through clinical program design, biomarker-driven patient selection, and payer engagement strategies that translate clinical benefit into credible health economic narratives.

Investor and corporate development activity is focused on capabilities that address the industry's most pressing bottlenecks: scalable vector production, automation of cell handling, robust analytics for potency and comparability, and digitized batch record systems. Across these company archetypes, success correlates with the ability to demonstrate reproducible manufacturing, credible clinical outcomes, and a commercialization plan that accounts for reimbursement complexity and international market entry barriers.

Actionable strategic priorities for leaders to strengthen supply resilience, scale manufacturing, align regulatory strategy, and accelerate payer adoption

Industry leaders should prioritize a set of pragmatic actions to translate scientific advantage into durable commercial success. First, strengthening supplier partnerships and dual sourcing for critical inputs will mitigate exposure to geopolitical and tariff-driven disruptions while enabling continuity of clinical supply. Simultaneously, investing in modular manufacturing capabilities and automation can reduce batch variability and improve unit economics, creating optionality for both in-house production and contract manufacturing partnerships. In parallel, establishing clear regulatory engagement plans that incorporate real-world evidence strategies and post-approval data collection will accelerate payer conversations and support outcome-based contracting models.

Operationally, organizations should accelerate digitalization of quality systems and batch analytics to enable more predictive manufacturing control and faster regulatory submissions. Cross-functional alignment between R&D, manufacturing, and commercial teams is essential: integrated project governance that links clinical milestones to manufacturing readiness and market access requirements will reduce delays during transition to late-stage development. Collaboration with healthcare providers to design feasible administration pathways-particularly for complex cell therapies requiring specialized infusion centers-will ensure patient access and streamline adoption.

Finally, scenario-based strategic planning that models tariff outcomes, regulatory shifts, and capacity constraints will help leadership teams prioritize investments and partnership choices. By combining supply chain resilience, manufacturing scalability, regulatory foresight, and payer-focused evidence generation, industry leaders can de-risk development pathways and create sustainable routes to patient access.

A rigorous mixed-methods research approach that combines primary stakeholder interviews, regulatory and patent analysis, and process mapping to validate operational and strategic insights

This analysis synthesizes multiple evidence streams to construct a robust and reproducible view of current dynamics in the cell and gene therapy sector. Primary research included structured interviews with stakeholders across discovery organizations, clinical development teams, manufacturing and supply chain leaders, regulatory affairs experts, and payers. Secondary research drew on peer-reviewed literature, publicly available regulatory guidance, clinical trial registries, company disclosures, patent filings, and logistics and cold-chain studies to triangulate operational and scientific trends.

Analytical methods included process mapping of manufacturing workflows to identify common bottlenecks, comparative regulatory analysis to surface jurisdictional variances, and qualitative coding of expert interviews to highlight recurring strategic themes. Scenario analysis was employed to evaluate the operational implications of tariff changes and supply chain disruptions. Where appropriate, findings were validated through cross-checks with subject matter experts to reduce bias and ensure technical accuracy. Limitations include the pace of innovation in the field, which can create rapid shifts in capability and regulation, and the variability of proprietary manufacturing processes that limit direct comparability across all developers.

Despite these constraints, the methodology emphasizes triangulation and expert validation to produce insights that are actionable for strategic decision-making, investment evaluation, and operational planning.

Concluding synthesis that links scientific progress to operational readiness and commercial pathways for achieving durable patient access and business sustainability

The cell and gene therapy field is entering a phase where strategic execution, not just scientific novelty, will determine which therapies achieve lasting clinical and commercial impact. Scientific advances continue to expand the range of treatable conditions and improve the precision of interventions, yet the path to patients demands concerted attention to manufacturing scale-up, supply chain robustness, regulatory alignment, and payer evidence generation. Leaders who proactively build resilient supplier networks, adopt modular manufacturing and digital quality systems, and engage payers with credible real-world evidence narratives will be best positioned to translate clinical success into broad patient access.

The interplay of regional regulatory approaches, tariff dynamics, and commercial models means that global strategies must be flexible and locally adapted. Organizations that blend platform investments with smart partnerships and that apply scenario planning to geopolitical and policy changes will reduce execution risk. Above all, integrating scientific, operational, and commercial planning across the organization will accelerate transitions from demonstration to widespread adoption, ensuring therapies reach the patients who need them while maintaining sustainable business models.

Taken together, these priorities offer a practical roadmap for converting innovation into impact in a competitive and rapidly evolving environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of allogeneic CAR T-cell therapies targeting solid tumors through universal donor platforms
• 5.2. Integration of CRISPR-based gene editing in in vivo therapies for rare genetic disorders to improve safety and efficacy
• 5.3. Adoption of automated closed-system manufacturing to reduce costs and scale production of personalized cell therapies
• 5.4. Development of next-generation AAV vector platforms to enhance tissue specificity and decrease immunogenicity in gene therapies
• 5.5. Implementation of decentralized point-of-care manufacturing models for on-site production of autologous cell therapies
• 5.6. Emergence of multi-specific and armored CAR T-cell constructs to overcome tumor microenvironment immunosuppression
• 5.7. Strategic partnerships between biotech firms and CDMOs to accelerate clinical development and commercialization of cell therapies
• 5.8. Regulatory harmonization efforts to streamline global approval pathways and accelerate patient access to gene treatments
• 5.9. Application of artificial intelligence and digital twins for process analytics and optimization in cell therapy manufacturing
• 5.10. Investment in supply chain innovations, including cryopreservation and cold chain logistics, to ensure cell product viability worldwide

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Market, by Therapy Type

• 8.1. Cell Therapy
  • 8.1.1. Stem Cell Therapies
    • 8.1.1.1. Hematopoietic Stem Cell Therapies
    • 8.1.1.2. Mesenchymal Stem Cell Therapies
  • 8.1.2. T Cell Therapy
    • 8.1.2.1. CAR T Cell Therapy
    • 8.1.2.2. T Cell Receptor (TCR)-based
• 8.2. Gene Therapy
  • 8.2.1. Ex Vivo Gene Therapy
  • 8.2.2. In Vivo Gene Therapy

9. Cell & Gene Therapy Market, by Delivery Method

• 9.1. Intramuscular
• 9.2. Intravenous

10. Cell & Gene Therapy Market, by Therapeutic Areas

• 10.1. Cardiovascular
  • 10.1.1. Congestive Heart Failure
  • 10.1.2. Ischemic Heart Disease
• 10.2. Metabolic Disorders
  • 10.2.1. Diabetes
  • 10.2.2. Obesity
• 10.3. Neurological Disorders
  • 10.3.1. Alzheimer's Disease
  • 10.3.2. Huntington's Disease
  • 10.3.3. Multiple Sclerosis
  • 10.3.4. Parkinson's Disease
  • 10.3.5. Spinal Cord Injuries
• 10.4. Oncology
  • 10.4.1. Hematological Malignancies
  • 10.4.2. Lymphomas
  • 10.4.3. Solid Tumors
• 10.5. Ophthalmology

11. Cell & Gene Therapy Market, by Application

• 11.1. Clinical Applications
  • 11.1.1. Disease Prevention
  • 11.1.2. Disease Treatment
• 11.2. Research & Development

12. Cell & Gene Therapy Market, by End User

• 12.1. Academic & Research Institutes
  • 12.1.1. Private Research Labs
  • 12.1.2. Universities
• 12.2. Hospitals & Clinics

13. Cell & Gene Therapy Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Cell & Gene Therapy Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Cell & Gene Therapy Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. AbbVie Inc.
  • 16.3.2. Abeona Therapeutics Inc.
  • 16.3.3. Adaptimmune Therapeutics PLC
  • 16.3.4. AGC Inc.
  • 16.3.5. Alnylam Pharmaceuticals, Inc.
  • 16.3.6. American Gene Technologies Inc.
  • 16.3.7. Amgen Inc.
  • 16.3.8. AnGes, Inc
  • 16.3.9. Astellas Pharma Inc.
  • 16.3.10. Becton, Dickinson and Company
  • 16.3.11. Biogen Inc.
  • 16.3.12. Bluebird Bio, Inc.
  • 16.3.13. BridgeBio Pharma, Inc.
  • 16.3.14. Bristol-Myers Squibb Company
  • 16.3.15. C.H. Boehringer Sohn AG & Co. KG
  • 16.3.16. Cellectis SA
  • 16.3.17. CRISPR Therapeutics AG
  • 16.3.18. F. Hoffmann-La Roche AG
  • 16.3.19. Gilead Sciences, Inc.
  • 16.3.20. Intellia Therapeutics, Inc.
  • 16.3.21. Ionis Pharmaceuticals, Inc.
  • 16.3.22. Johnson & Johnson Services Inc.
  • 16.3.23. Kyowa Kirin Co., Ltd.
  • 16.3.24. Merck KGaA
  • 16.3.25. Moderna, Inc.
  • 16.3.26. Mustang Bio, Inc.
  • 16.3.27. Novartis AG
  • 16.3.28. Novo Nordisk A/S
  • 16.3.29. Pfizer, Inc.
  • 16.3.30. REGENXBIO Inc.
  • 16.3.31. Sangamo Therapeutics, Inc.
  • 16.3.32. Sarepta Therapeutics, Inc.
  • 16.3.33. Shoreline Biosciences
  • 16.3.34. Sibiono GeneTech Co. Ltd.
  • 16.3.35. Syncona Limited
  • 16.3.36. Thermo Fisher Scientific Inc.
  • 16.3.37. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

• FIGURE 1. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CELL & GENE THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 259. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 260. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 261. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 262. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 263. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 264. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 265. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2024 (USD MILLION)
• TABLE 266. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2025-2032 (USD MILLION)
• TABLE 267. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 268. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 269. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
• TABLE 270. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
• TABLE 271. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 272. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 273. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 274. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 275. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
• TABLE 276. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
• TABLE 277. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 278. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
• TABLE 279. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
• TABLE 280. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
• TABLE 281. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 282. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 283. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 284. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 285. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 286. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 287. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 288. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 289. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
• TABLE 290. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
• TABLE 291. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 292. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 293. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 294. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 295. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 296. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 297. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2024 (USD MILLION)
• TABLE 298. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2025-2032 (USD MILLION)
• TABLE 299. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 300. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2025-2032 (USD MILLION)
• TABLE 301. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
• TABLE 302. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
• TABLE 303. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 304. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 305. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
• TABLE 306. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
• TABLE 307. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
• TABLE 308. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
• TABLE 309. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 310. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
• TABLE 311. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
• TABLE 312. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD M